Search
  • Quick Search in Journals
  • Quick Search anywhere
  • Quick search in Citations
Advanced Search
Menu
  • Information
    • Previous
    Next
    Original ResearchFree Access

    Association between Hepatic Triglyceride Content and Left Ventricular Diastolic Function in a Population-based Cohort: The Netherlands Epidemiology of Obesity Study

    Published Online:Jan 26 2016https://doi.org/10.1148/radiol.2015150035

    Abstract

    Fatty liver itself could, at least in obesity, pose a risk of myocardial dysfunction above and beyond known cardiovascular risk factors that are clustered within the metabolic syndrome.

    Purpose

    To investigate the association between hepatic triglyceride content and left ventricular (LV) diastolic function while taking potential confounding factors into account, including the components of the metabolic syndrome.

    Materials and Methods

    The study was approved by the institutional review board, and all participants gave informed consent. In this cross-sectional analysis of baseline data from the Netherlands Epidemiology of Obesity study, a population-based, prospective cohort study, participants (45% men; mean age ± standard deviation, 55.3 years ± 6.2) underwent magnetic resonance (MR) spectroscopy and MR imaging to assess hepatic triglyceride content and LV diastolic heart function (ratio of peak filling rates of the early filling phase and atrial contraction [E/A ratio]). Multivariate linear regression analysis was performed while adjusting for confounding factors, and results were additionally stratified according to body mass index.

    Results

    Adjustment for age, sex, heart rate, alcohol consumption, pack-years of smoking, all components of the metabolic syndrome, and visceral adiposity attenuated crude observed associations. A 10-fold increase in hepatic triglyceride content was associated with a change in mean E/A ratio of −0.004 (95% confidence interval [CI]: −0.134, 0.125) in the total study population, −0.194 (95% CI: −0.430, 0.042) in the normal-weight subgroup, 0.079 (95% CI: −0.090, 0.248) in the overweight subgroup, and −0.109 (95% CI: −0.186, −0.032) in the obese subgroup.

    Conclusion

    Fatty liver itself could, at least in obesity, pose a risk of myocardial dysfunction above and beyond known cardiovascular risk factors that are clustered within the metabolic syndrome. The association in the obese subgroup was small, and future studies with larger samples sizes are required to investigate to what extent the association exists and differs in normal-weight, overweight, and obese persons to unravel its clinical relevance.

    © RSNA, 2016

    Online supplemental material is available for this article.

    References

    • 1. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89(6):2583–2589. Crossref, Medline, Google Scholar
    • 2. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17(11):1136–1143. Crossref, Medline, Google Scholar
    • 3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363(14):1341–1350. Crossref, Medline, Google Scholar
    • 4. Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29(6):1325–1330. Crossref, Medline, Google Scholar
    • 5. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005;11(31):4838–4842. Crossref, Medline, Google Scholar
    • 6. Rijzewijk LJ, Jonker JT, van der Meer RW et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010;56(3):225–233. Crossref, Medline, Google Scholar
    • 7. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008;88(2):389–419. Crossref, Medline, Google Scholar
    • 8. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol 1997;30(1):8–18. Crossref, Medline, Google Scholar
    • 9. Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113–1132. Crossref, Medline, Google Scholar
    • 10. Simms MG, Walley KR. Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion. Am J Physiol 1999;277(1 Pt 2):H253–H260. Medline, Google Scholar
    • 11. Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288(2):E462–E468. Crossref, Medline, Google Scholar
    • 12. Pattynama PM, De Roos A, Van der Wall EE, Van Voorthuisen AE. Evaluation of cardiac function with magnetic resonance imaging. Am Heart J 1994;128(3):595–607. Crossref, Medline, Google Scholar
    • 13. Paelinck BP, Lamb HJ, Bax JJ, Van der Wall EE, de Roos A. Assessment of diastolic function by cardiovascular magnetic resonance. Am Heart J 2002;144(2):198–205. Crossref, Medline, Google Scholar
    • 14. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735–2752. Crossref, Medline, Google Scholar
    • 15. van der Meer RW, Hammer S, Lamb HJ et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab 2008;93(7):2702–2708. Crossref, Medline, Google Scholar
    • 16. Naressi A, Couturier C, Devos JM et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12(2-3):141–152. Crossref, Medline, Google Scholar
    • 17. Kim NH, Park J, Kim SH et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014;100(12):938–943. Crossref, Medline, Google Scholar
    • 18. Fotbolcu H, Yakar T, Duman D et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010;17(5):457–463. Medline, Google Scholar
    • 19. Goland S, Shimoni S, Zornitzki T et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40(10):949–955. Crossref, Medline, Google Scholar
    • 20. Fallo F, Dalla Pozza A, Sonino N et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009;19(9):646–653. Crossref, Medline, Google Scholar
    • 21. Bonapace S, Perseghin G, Molon G et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012;35(2):389–395. Crossref, Medline, Google Scholar
    • 22. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38(1):64–80. Crossref, Medline, Google Scholar
    • 23. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132(6):2169–2180. Crossref, Medline, Google Scholar
    • 24. Ng AC, Auger D, Delgado V et al. Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T₁ mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging 2012;5(1):51–59. [Published correction appears in Circ Cardiovasc Imaging 2012;5(2):e25.] Crossref, Medline, Google Scholar
    • 25. Perseghin G, Lattuada G, De Cobelli F et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008;47(1):51–58. Crossref, Medline, Google Scholar
    • 26. Ge F, Hu C, Hyodo E et al. Cardiomyocyte triglyceride accumulation and reduced ventricular function in mice with obesity reflect increased long chain fatty acid uptake and de novo fatty acid synthesis. J Obes 2012;2012:205648. Crossref, Medline, Google Scholar
    • 27. van Heerebeek L, Hamdani N, Handoko ML et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117(1):43–51. Crossref, Medline, Google Scholar
    • 28. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29(7):939–960. Crossref, Medline, Google Scholar
    • 29. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51(11):1947–1953. Crossref, Medline, Google Scholar
    • 30. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104–S112. Crossref, Medline, Google Scholar
    • 31. Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011;12(1):10–16. Crossref, Medline, Google Scholar
    • 32. Idilman IS, Aniktar H, Idilman R et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267(3):767–775. Link, Google Scholar
    • 33. Yokoo T, Bydder M, Hamilton G et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009;251(1):67–76. Link, Google Scholar

    Article History

    Received January 6, 2015; revision requested March 30; revision received September 9; accepted October 2; final version accepted October 16.
    Published online: Jan 26 2016
    Published in print: May 2016